Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059926 | 0.86 | NUDT1 (0.40) | NUDT1MAPK1 | |
| SCHEMBL15753484 | 0.82 | HPGDS (0.47) | NUDT1POLBMAPK1KMT2AAURKA | |
| SCHEMBL13759613 | 0.81 | ATR (0.42) | NUDT1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL5259159 | 0.81 | NUDT1 (0.39) | NUDT1MAPK1KDR | |
| SCHEMBL14062242 | 0.80 | PIK3C3 (0.49) | NUDT1 | |
| SCHEMBL3882473 | 0.75 | KMT2A (0.37) | NUDT1NTRK1KDM4EGLAPOLB | |
| SCHEMBL627350 | 0.72 | KDM4E (0.59) | NTRK1KDM4EGLAPOLBMAPK1 | |
| SCHEMBL15753311 | 0.72 | GSK3B (0.55) | — | |
| SCHEMBL23877021 | 0.71 | TRPA1 (0.45) | KDM4EALDH1A1SMN1; SMN2KDR | |
| SCHEMBL21206911 | 0.71 | RAB9A (0.61) | KDM4EPOLBMAPK1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566784-B2 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1742948-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | NUDT1 1199/4885NTRK1 837/4885ELANE 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.